PMID- 32517588
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Apr
TI  - FOXL2 expression might be a novel prognostic biomarker in patients with laryngeal 
      squamous cell carcinoma.
PG  - 300060520919252
LID - 10.1177/0300060520919252 [doi]
LID - 0300060520919252
AB  - OBJECTIVES: This study aimed to explore the expression profile of the Forkhead 
      box protein L2 gene (FOXL2) and to determine its prognostic value and associated 
      epigenetic and genetic alterations in patients with laryngeal squamous cell 
      carcinoma (LSCC). MATERIALS AND METHODS: Data for a subset of patients with LSCC 
      (N = 116) were extracted from the head and neck squamous cell carcinoma dataset 
      of The Cancer Genome Atlas and analyzed in relation to FOXL2 expression and 
      survival. RESULTS: Aberrant FOXL2 expression was an independent prognostic factor 
      for progression-free survival (PFS) (hazard ratio (HR): 2.63, 95% confidence 
      interval (CI): 1.34-5.18) and overall survival (OS) (HR: 2.39, 95%CI: 1.28-4.46). 
      Two gene-body CpG sites (cg10554436 and cg23637494) were moderately and 
      positively correlated with FOXL2 expression. DNA amplification (+2/+1) was common 
      (82/115, 71%) in LSCC, and FOXL2 expression was significantly upregulated in the 
      high-amplification group (+2) compared with copy-neutral (0) cases. CONCLUSION: 
      Aberrant FOXL2 expression may be a novel prognostic biomarker for PFS and OS 
      among patients with LSCC. FOXL2 upregulation may be related to gene-body 
      hypermethylation and DNA amplification.
FAU - Ge, Jun
AU  - Ge J
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan, China.
FAU - Jiang, Li
AU  - Jiang L
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan, China.
FAU - Tian, Yuke
AU  - Tian Y
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan, China.
FAU - Zheng, Min
AU  - Zheng M
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan, China.
FAU - Huang, Meiling
AU  - Huang M
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan, China.
FAU - Li, Juan
AU  - Li J
AUID- ORCID: 0000-0003-1477-0412
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (FOXL2 protein, human)
RN  - 0 (Forkhead Box Protein L2)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - *Carcinoma, Squamous Cell/diagnosis/genetics
MH  - Forkhead Box Protein L2/genetics
MH  - *Head and Neck Neoplasms
MH  - Humans
MH  - *Laryngeal Neoplasms/diagnosis/genetics
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck
PMC - PMC7218937
OTO - NOTNLM
OT  - FOXL2
OT  - Laryngeal squamous cell carcinoma
OT  - copy number alteration
OT  - methylation
OT  - prognosis
OT  - survival
EDAT- 2020/06/11 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/04/28
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/04/28 00:00 [pmc-release]
AID - 10.1177_0300060520919252 [pii]
AID - 10.1177/0300060520919252 [doi]
PST - ppublish
SO  - J Int Med Res. 2020 Apr;48(4):300060520919252. doi: 10.1177/0300060520919252.